(Q38211115)

31 August 2017

The status of surgery in the management of high-risk prostate cancer (English)

1 reference

31 August 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24818848%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Sailaja Pisipati

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24818848%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Datesh Daneshwar

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24818848%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Mark Wright

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24818848%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Edward Rowe

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24818848%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

David Gillatt

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24818848%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Raj Persad

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24818848%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Anthony Koupparis

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24818848%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

English

0 references

publication date

13 May 2014

1 reference

31 August 2017

Nature Reviews Urology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24818848%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24818848%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24818848%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

342-351

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24818848%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrurol.2014.100

2 June 2020

exact match

0 references

cites work

Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

High-risk prostate cancer in the United States, 1990-2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Improved sensitivity for detecting micrometastases in pelvic lymph nodes by real-time reverse transcriptase polymerase chain reaction (RT-PCR) compared with conventional RT-PCR in patients with clinically localized prostate cancer undergoing radical

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Time trends and local variation in primary treatment of localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Guideline for the management of clinically localized prostate cancer: 2007 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

An update on randomized clinical trials in advanced and metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Is there still a role for neoadjuvant therapy in breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Radical prostatectomy versus observation for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

What are the outcomes of radical prostatectomy for high-risk prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Locally advanced prostate cancer: a population-based study of treatment patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Changing nature of high risk patients undergoing radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Inaccuracies in assignment of clinical stage for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Robotic radical prostatectomy as the initial step in multimodal therapy for men with high-risk localised prostate cancer: initial experience of 160 men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Quality of life in patients undergoing salvage procedures for locally recurrent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Salvage prostatectomy in patients who have failed radiation therapy or cryotherapy as primary treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Surgery for high-risk localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Nerve-sparing robotic prostatectomy in preoperatively high-risk patients is safe and efficacious

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Radical prostatectomy in high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

NCCN clinical practice guidelines in oncology: prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiation therapy in the treatment of intermediate-risk prostate cancer - long term results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Urethral strictures following high-dose-rate brachytherapy for prostate cancer: analysis of risk factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Treatment of locally advanced prostate cancer: is chemotherapy the next step?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Metastatic nonseminomatous germ cell tumors of the testis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of ≥8

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Quality of life and satisfaction with outcome among prostate-cancer survivors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Adjuvant radiotherapy following radical prostatectomy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Radical prostatectomy for clinical stage T3a disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Intermediate-Term Potency, Continence, and Survival Outcomes of Radical Prostatectomy for Clinically High-Risk or Locally Advanced Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.100

Current options in the management of clinical stage C prostatic carcinoma.

31 March 2020

1 reference

12 December 2020

Impact of previous local treatment for prostate cancer on subsequent metastatic disease

1 reference

12 December 2020

Role of surgery in high-risk localized prostate cancer.

1 reference

12 December 2020

Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis

1 reference

12 December 2020

Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison

1 reference

12 December 2020

Late toxicity rates following definitive radiotherapy for prostate cancer.

1 reference

12 December 2020